This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $82.16 in the latest trading session, marking a -0.46% move from the prior day.
Is SPDR Portfolio S&P 500 High Dividend ETF (SPYD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for SPYD
Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
Here's Why You Should Add Ligand (LGND) Stock to Your Portfolio
by Zacks Equity Research
Ligand's (LGND) proprietary platforms enable it to form partnerships with several leading drug companies, providing it with funds through milestone and royalty payments.
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $83.24, marking a +0.33% move from the previous day.
Bristol Myers' (BMY) Breyanzi Gets Positive CHMP Opinion
by Zacks Equity Research
Bristol Myers (BMY) receives a positive CHMP opinion for CAR T cell therapy with Breyanzi for relapsed or refractory large B-cell lymphoma after one prior treatment.
Should iShares Select Dividend ETF (DVY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DVY
Should Franklin U.S. Low Volatility High Dividend Index ETF (LVHD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for LVHD
IGM Biosciences, Inc. (IGMS) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 22.22% and 0.80%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Arcellx, Inc. (ACLX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arcellx, Inc. (ACLX) delivered earnings and revenue surprises of -7.04% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $80.99 in the latest trading session, marking a +1.77% move from the prior day.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug Approval
by Zacks Equity Research
Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.
Is iShares Select Dividend ETF (DVY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DVY
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $77.81 in the latest trading session, marking a -1.68% move from the prior day.
Gilead (GILD) Announces OS Data on Yescarta From ZUMA-7 Study
by Zacks Equity Research
Gileads Yescarta shows statistically significant improvement in overall survival for initial treatment of R/R LBCL patients versus historical standard of care in curative setting.
Should SPDR Russell 1000 Yield Focus ETF (ONEY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ONEY
Gilead (GILD) Exercises Option to License Nurix's Candidate
by Zacks Equity Research
Gilead (GILD) exercises an option under its collaboration agreement with Nurix to license the latter???s investigational targeted protein degrader molecule NX 0479.
Nurix's (NRIX) Stock Up Due to License Option Exercise by Gilead
by Zacks Equity Research
Nurix Therapeutics (NRIX) to earn an option fee of $20 million as partner Gilead exercised its option to exclusively license Nurix's investigational targeted protein degrader molecule NX 0479.
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $79.85 in the latest trading session, marking a +0.25% move from the prior day.
Gilead (GILD) Gains 34% in 12 Months: Will the Trend Sustain?
by Zacks Equity Research
Gilead (GILD) gains 34% in the past 12 months as its HIV business and rapidly growing oncology business maintain momentum despite volatility.
Gilead Sciences (GILD) Stock Moves -0.15%: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $79.65, marking a -0.15% move from the previous day.
Is SPDR Russell 1000 Yield Focus ETF (ONEY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for ONEY
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB